Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

App aims to make cannabis use safer for regular users

NCT ID NCT07157540

Knowledge-focused Sponsor: Jacques Gaume Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a digital web application can help regular cannabis users adopt protective strategies to lower cannabis-related risks. About 565 adults in Lausanne, Switzerland, who already take part in a cannabis sales regulation pilot, will use the app freely and complete surveys every six months. Researchers compare different app modules to see which ones work best for harm reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 565 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible participants will be those included in the pilot trial of cannabis sales regulation in Lausanne, Switzerland (Cann-L study). Inclusion criteria in Cann-L study are: * being adult (\>18 years old), * having current cannabis use (i.e., use at least once a month over the last 6 months) * living in the city of Lausanne. To enter the study, they complete an entry assessment verifying their age and proof of residence, and confirming that they have current cannabis use. Exclusion Criteria: * Cann-L exclusion criteria comprise: * being younger than 18 years old, * being pregnant or breastfeeding, * having a health condition contraindicating the use of cannabis (e.g., severe psychiatric disorder). The consent to participate in the Cann-L parent trial comprises an option to be contacted to participate in sub-studies, including studies on prevention measures. All participants having accepted to be so contacted will be proposed to participate in the present study. Therefore, additional exclusion criteria for the present study include: * not providing informed consent to participate in sub-studies, including studies on prevention measures, * not providing informed consent to participate in the present study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Harm Reduction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cannabis use Harm reduction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lausanne University Hospital

    Lausanne, Vaud Canton, 1011, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.